The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $481.56, ...

Vertex Pharmaceuticals ( NASDAQ: VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...

Discover how Vertex Pharmaceuticals achieved 12% Q2 2025 revenue growth with new launches like ALYFTREK, CASGEVY, & JOURNAVX.

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...

Vertex Pharmaceuticals, trading at $469.50, is under scrutiny post-Q1 earnings, having moved in sync with the market. Its ...

Some Boston public school students are spending their summer vacations learning and working at a global biotech company.

Since its debut, Google's AI video generation model, Veo, has shown some incredible potential. That potential is clearly ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.